U.S. Markets open in 7 hrs 35 mins
  • S&P Futures

    3,792.00
    -29.25 (-0.77%)
     
  • Dow Futures

    30,807.00
    -192.00 (-0.62%)
     
  • Nasdaq Futures

    11,586.25
    -104.75 (-0.90%)
     
  • Russell 2000 Futures

    1,708.20
    -13.20 (-0.77%)
     
  • Crude Oil

    110.09
    +0.31 (+0.28%)
     
  • Gold

    1,816.20
    -1.30 (-0.07%)
     
  • Silver

    20.68
    -0.06 (-0.28%)
     
  • EUR/USD

    1.0458
    +0.0014 (+0.1360%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    28.16
    -0.20 (-0.71%)
     
  • GBP/USD

    1.2147
    +0.0025 (+0.2077%)
     
  • USD/JPY

    136.3900
    -0.1550 (-0.1135%)
     
  • BTC-USD

    19,998.36
    -113.47 (-0.56%)
     
  • CMC Crypto 200

    429.64
    -10.02 (-2.28%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,368.94
    -435.66 (-1.63%)
     

CinCor Pharma to Present at the Jefferies Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
CinCor Pharma Inc
CinCor Pharma Inc

WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 AM EDT.

A link to the live webcast is available at webcast/jefferies. An archived replay of the presentation will be available for 90 days at CinCor.com/events.

The CinCor management team will also participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.

About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

About Baxdrostat (CIN-107)
Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases. It is estimated that as much as 20% of the global population suffers from hypertension, including nearly one-half of the adult population in the U.S., or 116 million hypertensive patients.

Contacts:

Investors:

Terry Coelho

Bob Yedid

CinCor Pharma, Inc.

LifeSci Advisors

EVP, CFO and CBDO

ir@CinCor.com